Vítor Soares Tardelli1, Thiago Marques Fidalgo2, Julian Santaella3, Silvia S Martins4. 1. Departamento de Psiquiatria, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil; Department of Epidemiology - Columbia University Mailman School of Public Health, New York, NY, United States. Electronic address: vstardelli@unifesp.br. 2. Departamento de Psiquiatria, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil. Electronic address: marquesfidalgo@yahoo.com. 3. Department of Epidemiology - Columbia University Mailman School of Public Health, New York, NY, United States. Electronic address: julian.santaella@gmail.com. 4. Department of Epidemiology - Columbia University Mailman School of Public Health, New York, NY, United States. Electronic address: ssm2183@columbia.edu.
Abstract
OBJECTIVES: To report and analyze prevalence's of Benzodiazepines (BZDs) and Prescription Opioids (POs) use by insurance status and to investigate associations between insurance status and BZDs, POs and concurrent medical/non-medical use and use disorders. METHODS: This study included 81,133 adults ages 18 and older from 2015 and 2016 National Survey on Drug Use and Health. Participants' self-reported past- year medical use, non-medical use and use disorders of BZDs and POs were assessed, along with their insurance status (Private/Military, Medicare, Medicaid, and Uninsured) and demographic characteristics. RESULTS: In 2015-2016, 12.6% of adults reported using BZDs and 36.9% reported using POs in the past year. Among adults, 8.3% reported past-year use of both BZDs and POs; also, 1.9% and 3.8% reported non-medical use of BZDs and POs, respectively, and 0.9% reported non-medical use of both BZDs and POs. Medicaid-covered respondents had higher risk of BZDs (aRRR = 1.59, 95%CI = [1.45, 1.74]), POs (aRRR = 1.66, 95%CI = [1.54, 1.79]) and concurrent past-year medical use (aRRR = 2.11, 95%CI = [1.87, 2.38]), higher risk of BZDs non-medical use (aRRR = 1.40, 95%CI = [1.17, 1.68]) and BZD Use Disorders (aRRR = 2.60, 95%CI = [1.82, 3.72]), POs non-medical use (aRRR = 1.67, 95%CI = [1.45, 1.92]), PO use Disorders (aRRR = 4.12, 95%CI = [3.33, 5.11]) and concurrent non-medical use (aRRR = 1.52, 95%CI = [1.20, 1.92]) and Use Disorders (aRRR = 3.68, 95%CI = [1.93, 6.78]), compared to those with private insurance. CONCLUSIONS: Future health policies should focus on reducing individual and co-prescription of BZDs and POs and providing different strategies of pain management.
OBJECTIVES: To report and analyze prevalence's of Benzodiazepines (BZDs) and Prescription Opioids (POs) use by insurance status and to investigate associations between insurance status and BZDs, POs and concurrent medical/non-medical use and use disorders. METHODS: This study included 81,133 adults ages 18 and older from 2015 and 2016 National Survey on Drug Use and Health. Participants' self-reported past- year medical use, non-medical use and use disorders of BZDs and POs were assessed, along with their insurance status (Private/Military, Medicare, Medicaid, and Uninsured) and demographic characteristics. RESULTS: In 2015-2016, 12.6% of adults reported using BZDs and 36.9% reported using POs in the past year. Among adults, 8.3% reported past-year use of both BZDs and POs; also, 1.9% and 3.8% reported non-medical use of BZDs and POs, respectively, and 0.9% reported non-medical use of both BZDs and POs. Medicaid-covered respondents had higher risk of BZDs (aRRR = 1.59, 95%CI = [1.45, 1.74]), POs (aRRR = 1.66, 95%CI = [1.54, 1.79]) and concurrent past-year medical use (aRRR = 2.11, 95%CI = [1.87, 2.38]), higher risk of BZDs non-medical use (aRRR = 1.40, 95%CI = [1.17, 1.68]) and BZD Use Disorders (aRRR = 2.60, 95%CI = [1.82, 3.72]), POs non-medical use (aRRR = 1.67, 95%CI = [1.45, 1.92]), PO use Disorders (aRRR = 4.12, 95%CI = [3.33, 5.11]) and concurrent non-medical use (aRRR = 1.52, 95%CI = [1.20, 1.92]) and Use Disorders (aRRR = 3.68, 95%CI = [1.93, 6.78]), compared to those with private insurance. CONCLUSIONS: Future health policies should focus on reducing individual and co-prescription of BZDs and POs and providing different strategies of pain management.
Authors: Elizabeth Gorevski; Boyang Bian; Christina M L Kelton; Jill E Martin Boone; Jeff J Guo Journal: Ann Pharmacother Date: 2012-03-27 Impact factor: 3.154
Authors: Jillian L Peters; Wesley M Durand; Kristina A Monteiro; Luba Dumenco; Paul George Journal: J Am Board Fam Med Date: 2018 Nov-Dec Impact factor: 2.657
Authors: Daniel T Hackman; Marion S Greene; Taya J Fernandes; Ashley M Brown; Eric R Wright; R Andrew Chambers Journal: J Clin Psychiatry Date: 2014-07 Impact factor: 4.384
Authors: Brandi P Cotton; Matthew C Lohman; Jessica M Brooks; Karen L Whiteman; Yuhua Bao; Rebecca L Greenberg; Martha L Bruce Journal: Home Healthc Now Date: 2017-06
Authors: Ron Carico; Xinhua Zhao; Carolyn T Thorpe; Joshua M Thorpe; Florentina E Sileanu; John P Cashy; Jennifer A Hale; Maria K Mor; Thomas R Radomski; Leslie R M Hausmann; Julie M Donohue; Katie J Suda; Kevin Stroupe; Joseph T Hanlon; Chester B Good; Michael J Fine; Walid F Gellad Journal: Ann Intern Med Date: 2018-10-09 Impact factor: 25.391
Authors: Jacob C Cogan; Rohit R Raghunathan; Melissa P Beauchemin; Melissa K Accordino; Elena B Elkin; Alexander Melamed; Jason D Wright; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2021-06-04 Impact factor: 4.872
Authors: Kara Suvada; Anna Zimmer; Jesse Soodalter; Jimi S Malik; Dio Kavalieratos; Mohammed K Ali Journal: BMJ Open Date: 2022-06-16 Impact factor: 3.006
Authors: Flavia Ismael; Beatriz Zaramella; Tatiane Battagin; João C S Bizario; Júlia Gallego; Victoria Villela; Lilian Bezerra de Queiroz; Fabio E Leal; Julio Torales; Antonio Ventriglio; Megan E Marziali; Priscila D Gonçalves; Silvia S Martins; João M Castaldelli-Maia Journal: Front Public Health Date: 2021-03-04